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Abstract: Antimicrobial peptides (AMPs) hold promise as the next generation of antimicrobial
agents, but often suffer from rapid degradation in vivo. Modifying AMPs with non-proteinogenic
residues such as peptoids (oligomers of N-alkylglycines) provides the potential to improve stability.
We have identified two novel peptoid-based compounds, B1 and D2, which are effective against the
canine skin pathogen Staphylococcus pseudintermedius, the main cause of antibiotic use in companion
animals. We report on their potential to treat infections topically by characterizing their release
from formulation and in vitro ADME properties. In vitro ADME assays included skin penetration
profiles, stability to proteases and liver microsomes, and plasma protein binding. Both B1 and D2
were resistant to proteases and >98% bound to plasma proteins. While half-lives in liver microsomes
for both were >2 h, peptoid D2 showed higher stability to plasma proteases than the peptide-peptoid
hybrid B1 (>2 versus 0.5 h). Both compounds were suitable for administration in an oil-in-water
cream formulation (50% release in 8 h), and displayed no skin permeation, in the absence or presence
of skin permeability modifiers. Our results indicate that these peptoid-based drugs may be suitable
as antimicrobials for local treatment of canine superficial pyoderma and that they can overcome the
inherent limitations of stability encountered in peptides.
Keywords: antimicrobial peptoids; peptidomimetics; in vitro ADME; topical formulation; metabolic
stability
1. Introduction
The emergence of bacterial pathogens resistant to multiple antimicrobial agents over the past
decades is a growing public health threat, and there is an urgent need for novel antimicrobial drugs
for human and veterinary use [1,2]. In companion animals, canine skin infections constitute the main
cause of antibiotic use [3]. Staphylococcus pseudintermedius is the primary pathogen of this disease, as it
is isolated from around 90% of canine clinical skin samples [4]. In the recent decade, the worldwide
emergence of methicillin-resistant S. pseudintermedius (MRSP) [5] has resulted in infections untreatable
with antimicrobial agents licensed for systemic use in dogs. Therefore, there is an urgent need to
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develop alternative antimicrobial agents to combat this pathogen. Furthermore, systemic administration
of antibiotics may promote the development of resistance and current guidelines encourage the
use of topical therapy for treatment of MRSP infections [6]. Peptides with antimicrobial activity
(AMPs) are the object of rapidly-growing research interest as the next generation of antibacterials [7–9].
In general, AMPs are small (<50 amino acids), cationic, amphipathic host defense peptides naturally
present in the innate immune systems [10]. AMPs generally show specificity for bacterial targets,
broad-spectrum activity and lower affinity for mammalian host cells [11–14]. Although promising,
they display limited stability in vivo being easily degraded by proteases [15]. In recent years, chemical
and structural modifications have been used as strategies for improving stability of peptides. Structural
analogues of peptides such as peptoids (polymers of N-substituted alkylglycines) [16,17] have been
introduced to overcome stability issues. Introduction of peptoid residues in the structure of existing
or de novo designed AMPs has also become a successful approach to improve their activity and
pharmacokinetic properties [15]. Whereas effort has been made to assess the structure-activity
relationship of antimicrobial peptoids to improve activity [18], their ADME (absorption, distribution,
metabolism and excretion) profile has not been investigated to the same extent. In the present study,
these aspects were characterized for a peptide-peptoid hybrid (B1) and a peptoid (D2) designed as
antimicrobials for topical use against S. pseudintermedius. The structures of B1 and D2 are shown in
Figure 1. First generation formulations of B1 and D2 for topical administration have been developed
and used for testing. The in vitro ADME profile of B1 and D2 in terms of degradation by metabolic
enzymes, plasma protein binding and permeation through excised dog skin were investigated in
this study.
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Figure 1. Structure of B1 (A) and D2 (B) both isolated as trifluoacetic acid salts.
2. Results
2.1. MIC and Hemolytic Activity In Vitro
B1 and D2 were selected after screening of a combinatorial library of de novo designed compounds
for their activity against S. pseudintermedius and host toxicity in vitro measured as lytic activity against
red blood cells. B1 and D2 were designed on the basis that the majority of antimicrobial peptides
are cationic and hydrophobic. We envisaged that short linear peptide-peptoid hybrids consisting of
cationic lysines and hydrophobic peptoid residues would result in derivatives with potent antibacterial
activity and low cytotoxicity. Minimum inhibitory concentrations against S. pseudintermedius were
2–4 µg/mL for B1 and 1–2 µg/mL for D2, irrespective of the strain being MSSP or MRSP. Preliminary
data suggest that B1 and D2 also are active against a wide range of canine pathogens (data not
shown, Greco et al., manuscript in preparation). The hemolytic activity of B1 and D2 as a function
of their concentration is shown in Figure 2. Repeated experiments on different days with different
human blood samples confirmed the results. The concentration of compound resulting in 10 and
50% hemolysis of erythrocytes (EC10 and EC50) were 64 µg/mL and 219 µg/mL for B1 and 128 µg/mL
and >256 µg/mL for D2. In a separate experiment, performing the test with dog blood resulted in
hemolysis at 150 µM of 45% and 22% for B1 and D2, respectively.
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Figure 2. Hemolytic activity of peptide-peptoid hybrid B1 and peptoid D2 in human erythrocytes as a
function of concentration. Mean ± SEM, n = 3.
2.2. Stability to Proteases
The stability of B1 and D2 w s tested against trypsin and chymotrypsin—proteases of mammalian
origin—and pronase, a mix of different enzymes extracted from bacterium Streptomyces griseus.
B1 and D2 were incubated singularly in different vials with trypsin, chymotrypsin, and pronase
at 37 ◦C (trypsin and pronase) and 30 ◦C (chymotrypsin), and the results were analyzed by comparing
areas of the resulting RP-HPLC peaks after 6 and 24 h. The peptide-peptoid hybrid B1 showed
6% degradation after 24 h of incubation with trypsin, 38% after pronase exposure, and no degradation
after α-chy otrypsin exposure (Figure 3). Peptoid D2 showed 0.2% degradation after 24 h incubation
with pronase, and no degradation was observed by trypsin and chymotrypsin (see Supplementary
Materials, Section S3).
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Figure 3. Proteoly ic degradation of peptide-peptoid hybrid B1 by ch motrypsin, trypsin, a d pronase.
2.3. Stability in Plasma
Plasma stability of B1 and D2 was tested as an estimation of their half-life in case of systemic
absorption or intravenous administration. Plasma stability was determined by incubation of a known
concentration of the peptoid/hybrid of interest with dog plasma up to 60 min at 37 ◦C and analyzing
the concentration of the peptide in the supernatant by LC-MS/MS after protein precipitation. Results
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are presented as average of triplicates from a single donor. Three peptides with known stability profiles
(Peptide 1–3) were used as controls in this study (see Table 1). B1 showed some degradation in plasma,
with a half-life of 28.9 minutes, while D2 showed no detectable degradation and a half-life > 120 min
(see Supplementary Materials, Section S6).
2.4. Stabilty in Liver Microsomes
Liver microsomal assay is used to determine hepatic intrinsic clearance of a drug and identification
and profile of metabolites across species. Evaluation of microsomal stability of compounds in different
species is common procedure in the drug discovery process to evaluate different metabolites in case
of instability. In vitro stability of B1 and D2 in liver microsomes was investigated by incubating
B1 and D2 with dog and human microsomes, and analyzing the resulting solution via LC-MS/MS
to determine the residual amount of B1 and D2 after microsomal degradation. Both B1 and D2 were
rather stable upon incubation with liver microsomes, both displaying in vitro half-lives >120 min
(Table 1). After 60 min, 77% of D2 and 100% of B1 were recovered.
Table 1. Half-lives (minutes) of B1 and D2 and control peptides 1 in plasma and liver microsomes.
Compound Plasma (Dog) Liver Microsomes (Dog) Liver Microsomes (Human)
B1 28.9 >120 >120
D2 >120 >120 >120
Peptide-1 >120 - -
Peptide-2 <3 - -
Peptide-3 81.2 - -
1 Peptide-1, -2, and -3 are control peptides with long, medium and short plasma half-life, respectively.
2.5. Plasma Protein Binding
The plasma protein binding properties of candidate drugs can influence their efficacy, safety,
and distribution. The fraction of peptoid bound to proteins of plasma collected from dogs was determined
using rapid equilibrium dialysis. Both B1 and D2 were highly bound (>98%) to dog plasma proteins
(Table 2). A free fraction of 0.16% of the peptide-peptoid hybrid B1 and 1.43% of the peptoid D2 were
detected via LC-MS/MS from dog plasma. Recoveries for both B1 and D2 were >70%.
Table 2. Protein binding of B1, D2, and control peptide after 4 h incubation in plasma.
Entry % Average Recovery SD 1 % Unbound Bound SD 1
B1 75.6 20.7 0.16 99.8 0.000
D2 70.8 6.5 1.43 98.6 0.005
Control 67.1 12.6 0.27 99.7 0.001
1 Mean ± SD (n = 4).
2.6. In Vitro Release
To identify a suitable carrier for B1 and D2, their release from three different formulations
(oil-in-water cream, 20% poloxamer gel and ointment, see Table 3 and Section 4.6) was investigated.
Release was evaluated as function of the amount of peptide diffused through a cellulose membrane in
the receptor of a Franz cell and detected via RP-HPLC from 0 to 8 h. Approximately 50% of the content
of both B1 and D2 was released from the oil-in-water cream over 8 h (Figure 4). The release kinetics
indicated zero-order kinetics, and rates were comparable for the two compounds. On the contrary,
no detectable release of B1 and D2 was observed from the 20% poloxamer gel and the ointment after
eight hours (data not shown).
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2.7. Skin Permeability
To evaluate the absorption of B1 and D2 nto systemic circulation after topical administration,
their in vitro permeation profile through excised dog skin was investigated in different excipient
conditions, with and without the presence of a skin permeability modifier (transcutol). For each
permeation study, donor chambers contained formulation at suitable concentration of peptoid for
UPLC detection of penetration of 1% of total content and every sample was present three times.
The experiment was repeated twice. Permeation was measured as a function of the concentration
detected in the donor chamber of a Franz cell apparatus. A representative chromatogram is shown in
Figure 5. No, or negligible, permeation (<1%) of B1 and D2 applied in any of the vehicles was detected
after 48 h, suggesting practically no skin penetration of B1 and D2. However, the presented results do
not rule out potential partitioning into the stratum corneum.
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Figure 5. Skin penetration of B1 from 50% transc t l for ulation d tected via UV-UPLC after 24 h.
No penetration of B1 through dog skin is observed (UV-UPLC detection limit: 1 µg/L). Since B1 and
D2 showed similar skin penetration pattern in all tested formulations, only representative data for B1
are shown.
3. Discussion
There is an urgent need for novel antibacterials specifically tailored for veterinary use only.
Developing such agents for veterinary medicine would address the current lack of therapeutic options
within this field, and reduce the use of critically important antibiotics approved for humans in the
treatment of animal infections [19–21].
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AMPs act quickly and selectively at micromolar concentrations, are rarely associated with
antimicrobial resistance, and can be structurally optimized by chemical synthesis [22–24]. Their main
limitations as therapeutics are their very short in vivo half-life and high production costs.
Despite this, to date several AMPs are under commercial development [25]. De novo design
of AMPs and peptidomimetics, such as peptoids [26–30], peptide-peptoid hybrids [31–33] and
α-peptide/β-peptoids [34,35] have been successful strategies to increase the in vivo stability.
The therapeutic potential of peptoids resides in their biological activity comparable to the parent
peptide, and their resistance to proteolytic degradation [36]. Despite the large interest in developing
peptoid-based antimicrobial agents, though, only a few studies on ADME properties of peptoid
exist [37–41]. However, these are mainly limited to short peptoids—up to four residues. In this
study, we describe a peptide-peptoid hybrid, B1, and a peptoid, D2, that were highly active against
S. pseudintermedius (MIC 2–4 µg/mL). Moreover, the in vitro ADME properties of these peptoid-based
antimicrobials were investigated in order to assess their potential as topical drug molecules to treat
canine pyoderma.
Topical antimicrobial treatment of canine superficial pyoderma is favorable to systemic treatment,
as very high concentrations can be reached at the site of infection. Furthermore, it minimizes the
side effects and resistance development in other body sites, including the intestinal tract [6]. Creams
and ointments are currently employed for the treatment of staphylococcal infections in veterinary
medicine [42] and AMPs formulated in ointments (neomycin, bacitracin and polymyxin B [43]),
cream (pexiganan) [44] and poloxamer gel (vancomycin) [45] are known.
To our knowledge there is no evidence in the literature of topical formulation studies of
peptoid-based molecules, although they have been indicated as promising compounds for topical
application [46]. To characterize the potential of B1 and D2 for topical treatment, we evaluated
their release from three potential formulations with different hydrophilicity features (a hydrogel,
an ointment and an oil-in-water cream), and assessed their permeation through canine skin. No release
was observed when B1 and D2 were formulated in a poloxamer gel or an ointment. Only oil-in-water
cream indicated suitability for topical delivery of B1 and D2.
The permeation across excised skin was found to be negligible for both compounds as expected
from their physicochemical properties. The skin permeability is often the most difficult challenge
to overcome for potential topical drugs [47]. Drugs with a molecular weight >500 Dalton are likely
to fail penetrating the SC, the external layer of the skin. Furthermore, the diffusion through skin of
positively charged peptides may be prevented by association with negatively charged constituents in
the skin [48]. To assess the permeation through skin, B1 and D2 were tested alone and in combination
with chemical penetration enhancers (ethanol and transcutol) modifying physical properties of the
SC [49,50]. Ethanol is widely used in topical applications and has been previously reported as a
skin-penetrating agent for its effect of lipid/protein extraction from the SC and for its “push effect” due
to evaporation [51]. Transcutol (diethylene glycol monoethylether) increases the solubility of drugs in
the skin and is frequently used as a transdermal penetration enhancer in recent years [49,52]. Even in
the presence of enhancers known to modify the physical properties of the SC [50], no permeation
was observed. These results overall indicate that B1 and D2 are suitable for topical administration to
skin. The lack of permeation likely predicts no systemic absorption of B1 and D2 following topical
administration in vivo. Skin penetration of peptides is generally difficult: as an example, a recent
paper reports of 5000 publications on formulation and clinical trials for the improvement of penetration
of cyclosporine [53], a naturally-occurring multiple N-methylated cyclic peptide with a MW similar
to D2. Further experiments are needed to evaluate the extent of the penetration of B1 and D2 into
the skin layers, and in case of skin lesions caused by pyoderma, including in vivo studies. However,
these initial results indicate that B1 and D2 are suitable for the treatment of superficial infections.
To characterize in vitro the behavior of B1 and D2 if systemically absorbed, their metabolic
stability, hemolytic activity, and plasma protein binding were evaluated along with their susceptibility
to proteolysis by trypsin, chymotrypsin and pronase. The peptide-peptoid hybrid B1 only showed
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6% degradation after 24 h of incubation with trypsin and 38% with pronase, while D2 was stable.
Our result is in good agreement with one of the earliest studies on stability of peptoids [54]. In that study,
homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers
were incubated with different proteases from each major class (carboxypeptidase A, chymotrypsin,
elastase, papain, pepsin, trypsin). The authors found that the analogues were virtually intact, while the
L-peptides were rapidly degraded.
In our study, the peptoid D2 was also stable to plasma proteases, while the initial concentration of
the peptide-peptoid hybrid B1 was halved in about 30 min. Results indicate an increased stability in dog
plasma conferred by the introduction of peptoid residues, while the presence of peptide bonds results in
lower stability. Furthermore, the N-terminus of a peptide correlates with its resistance to proteolysis in
plasma [15], and that may correspond to the decreased metabolic stability of the peptide-peptoid hybrid
B1 as well. Although the cleavage site is not known with certainty, the presence of two N-terminal
Lys residues suggests the site of proteolytic susceptibility. Stability to proteases is also relevant when
considering topical applications, due to the presence of proteolytic enzymes of bacteria and skin.
In one of the few studies addressing the in vivo pharmacokinetics of peptoids, [37] compared the
distribution of a tripeptoid and a tetrapeptide after IV administration. The peptoid was not degraded
and rapidly excreted, while the degradation products of the peptide were detected in peripheral body
sites [37]. Similar results were reported by [41], who reported complete metabolic degradation of a
labelled tripeptide in blood after two hours compared to stability of a labelled tripeptoid.
Both B1 and D2 showed good stability to in vitro degradation by liver microsomes, an assay which
has been previously reported to correlate with in vivo data [55]. Half-lives for B1 and D2 were higher
than 2 h, indicating a trend of low-medium clearance, compared to controls with known behavior.
This suggests that B1 and D2 are not readily susceptible to degradation by liver metabolism. Furthermore,
the skin contains metabolizing enzymes similar to the liver (CYP and UDP-glucuronosyltransferase) [56],
hence, the assay may aid in predicting stability after cutaneous administration.
Toxicity is an important issue when developing antimicrobial agents. Hemolysis is a standard
assay used when screening antimicrobial peptides. The concentration of B1 resulting in 50% of human
blood hemolysis was close to 256 µg/mL, comparable to approximately 100× MIC, while hemolysis
of D2 at the highest concentration tested did not reach 30%. A similar trend also appeared when the
experiment was repeated with dog blood. This could be explained by the higher structural flexibility
of peptoid chains compared to peptides and a different type interaction with erythrocyte membranes.
The absence of backbone hydrogen bonds in peptoids prevents backbone-driven aggregation and
makes peptoids better membrane permeating agents [57]. Compared to B1, the peptoid D2 has a
reduced number of hydrogen donors due to the peptoid backbone, higher hydrophilicity (featuring
five positive charges, see Figure 1) and a higher degree of rotational flexibility. Rotational flexibility [58]
is generally directly proportional to molecular weight, and it counts non-ring bonds to nonterminal
non-hydrogen atoms. Despite the promising results, toxicity needs to be further assessed, e.g.,
by cytotoxicity to fibroblasts or other skin cells, as well as in vivo.
Both B1 and D2 have high protein binding, as both were >98% bound to plasma proteins in
equilibrium dialysis in vitro. Plasma protein binding is also likely to occur with administration to a
site of infection. Other antimicrobial peptides and drug candidates are also highly protein bound [59],
especially apolipoprotein and serum albumin. Despite some inhibition of antimicrobial activity [60],
these compounds retained part of their antimicrobial activity and, furthermore, were less cytotoxic at
the site of action [61].
4. Materials and Methods
4.1. Synthesis and Characterization of Peptide-Peptoid Hybrid (B1) and Peptoid (D2)
HOAt (1-hydroxy-7-azabenzotriazole) and HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) were from GL Biochem Shanghai (Shanghai,
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China). The compounds 1-naphthylmethylamine, 4-methylbenzylamine, butylamine, DIPCDI (NN-
diisopropylcarbodiimide), DIEA (diisopropylamine) and TIS (triisopropylsilane) were from Sigma-Aldrich
(Copenhagen, Denmark. TentaGel SRAM (loading 0.2 mmol/g), TFA (trifluoroacetic acid), piperidine,
and Fmoc-protected amino acids were purchased from Iris-Biotech GmbH (Marktredwitz, Germany).
Disposable 5-mL polypropylene reactors fitted with a PTFE filter were acquired from Thermo Scientific
(Hvidovre, Denmark).
Acetic acid and DMF (dimethylformamide), DCM (dichloromethane), ACN (acetonitrile) were
purchased from VWR (Copenhagen, Denmark). All reagents and solvents were used without
further purification. The manual solid-phase synthesis of peptide-peptoid hybrid B1 and peptoid
D2 were carried out in disposable syringes on 100 mg of TentaGel S RAM (loading 0.2 mmol/g)
using Fmoc chemistry for amino acids and the submonomer approach for peptoid building blocks
as previously described [31]. Following synthesis, the product was cleaved from the resin using
TFA/H2O/triisopopylsilane (95:2.5:2.5). Crude products were purified by preparative RP-HPLC until
≥97% purity was obtained (determined by analytical RP-HPLC (Waters Corporation, Milford, MA USA)).
The identity of the products was verified by MALDI-TOF-MS (Bruker Daltonik GmbH, Bremen, Germany)
(see supplementary information, Section S2).
4.2. Minimum Inhibitory Concentration
The antimicrobial activity of B1 and D2 was investigated by determining their minimum
inhibitory concentration (MIC) against a methicillin-susceptible and a methicillin-resistant strain
of Staphylococcus pseudintermedius isolated from canine skin and ears at the Veterinary Diagnostic
laboratory at University of Copenhagen, Denmark. Assays were performed by microbroth dilution
of test compounds in Mueller-Hinton broth (MHB) in microtiter plates (Corning 96-well clear
polypropylene round bottom plates, non-treated) according to the Clinical and Laboratory Standard
Institute guidelines [62]. The compounds were tested in concentrations ranging from 1 to 64 µg/mL
(1, 2, 4, 8, 16, 32, 64 µg/mL). Briefly, bacteria were streaked on blood agar plates and incubated
overnight at 37 ◦C. From these plates, colonies were suspended in saline solution and adjusted
by nephelometer to obtain turbidity equivalent to a 0.5 McFarland standard. The suspension was
diluted 1:100 in sterile 0.9% (w/v) saline, and 50 µL of this suspension was transferred to each well
of the microtiter plate containing 50 µL of peptide solution in water, resulting in a concentration of
5 × 105 CFU/well. The microtiter plate was sealed and incubated at 35 ◦C for 16–20 h. Results were
read by visual inspection.
4.3. Hemolytic Activity
EC10 and EC50 values represent concentrations that result in 10 and 50% hemolysis, respectively.
The EC10 and EC50 values were determined for B1 and D2, as previously described [63]. Briefly, two-fold
serial dilutions (1 to 256 µg/mL) were incubated in PBS with a suspension of freshly withdrawn human
red blood cells in PBS in 96-well v-shaped microtiter plates at 37 ◦C for 1 h covered with Microseal foil to
avoid evaporation, and transferred to 96-well flat bottomed microtiter plates. The release of hemoglobin
was detected by measuring the absorbance at 414 nm by a UV spectrophotometer (VERSAmax™ Tunable
Microplate Reader, Molecular Devices, San José, CA, USA). PBS and melittin were used as negative and
positive controls, respectively. All human blood samples were obtained after informed consent of the
voluntary donors upon understanding of the research purposes, within local hospitals and according to
local guidelines.
4.4. Stability of Peptide-Peptoid Hybrid (B1) and Peptoid (D2)
4.4.1. Stability to Proteases
The effect of proteases on B1 and D2 was tested by incubation of the compounds at 37 ◦C
with three commercially-available proteases (trypsin and α-chymotrypsin from bovine pancreas,
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and pronase from Streptomyces griseus, all purchased from Sigma Aldrich). Solutions, concentrations,
and reaction temperatures were selected according to manufacturer’s recommendations for total
peptide digestion. A stock solution of 1 mM trypsin was prepared in 1 mM Tris HCl buffer solution
containing 20 mM Ca2+. For the proteolytic stability assay, a 10 µg/mL trypsin concentration and
1 mg/mL concentration of B1 and D2 in 0.1 M Tris buffer were used to obtain a 1:100 enzyme:peptide
ratio. Reaction was conducted at 37 ◦C for 6 h. Chymotrypsin was solubilized at 10 mg/mL in 1 mM
HCl solution containing 2 mM CaCl2. A ratio of 1:60 chymotrypsin: peptide was used (17 µg/mL
chymotrypsin, 1 mg/mL peptide). Chymotrypsin reaction was conducted in 100 mM Tris HCl
containing 10 mM CaCl2, pH 7.8 at 30 ◦C. The reaction with pronase was conducted, following the
enzyme producer’s recommendation, using 0.2 µM B1 and D2 and 1% pronase powder (w/w) in
50 mM ammonium bicarbonate buffer at pH 8 at 37 ◦C. At time 0, 3, and 6 h, 50 µL aliquots were
removed for RP-HPLC analysis (see supplementary Materials, Section S3).
4.4.2. Stability in Plasma
Dog plasma was collected from a single Beagle dog at the research facilities of Zoetis Animal
Health (Kalamazoo, MI, USA) and frozen immediately until use. Proprietary linear peptides with a
short and medium half-life and a cyclic peptide with a long half-life were used as controls (Table 2).
B1, D2, and controls were diluted to 10 µM in 2% (w/v) BSA containing 0.2% (v/v) formic acid to prevent
non-specific binding to materials. Test compounds were added to plasma diluted 1:1 with PBS buffer pH
7.4 and preheated for 5 min at 37 ◦C. Samples were removed at 0, 5, 10, 20, 30, and 60 min. The reaction was
stopped by protein precipitation by adding a 9:1 (v/v) ACN:MeOH mixture followed by centrifugation
at 10,000 rpm for 5 min, and the remaining amount of intact test compounds in the supernatant was
quantified via API Sciex 4000Q LC-MS/MS (Framingham, MA, USA) (coupled with an HPLC column to
filter off the plasma proteins—see Supplementary Materials, Section S6) upon completion of the assay.
Experiments were performed in quadruplicate. The half-life values were calculated on the basis of the
rate of substrate disappearance (Equation (1)) and calculating the in vitro half-lives (t12 ) (Equation (2)):
% compound remaining = Ae−kt, (1)
where k is the rate constant for disappearance of parent compound, t is time and A is the starting
concentration and is close to 100 when data is normalized to the zero time point:
t1/2 = 0.693/k, (2)
4.4.3. Stability to Liver Microsomes
Evaluation of stability of B1 and D2 to the enzymes in liver microsomes was performed with a
robotic system for liquid handling (Hamilton Microlab STAR, Hamilton Robotics, Reno, NV, USA).
Dog and human microsomes were obtained from XenoTech LLC (Kansas City, KS, USA) and
reconstituted in buffer containing D-(L)-isocitrate trisodium salt and 10 U/mL isocitrate dehydrogenase
type IV glycerol solution (procine). A stock solution of 10 mM substrate (B1, D2 or controls, proprietary
peptides of Zoetis, Kalamazoo, MI, USA) was diluted 1:1000 in 1% (v/v) ACN before adding to
the reaction mixture. The reaction was initiated by adding NADPH and substrate to reconstituted
microsomes. A final concentration of 1 µM substrate was incubated with 0.5 mg/mL microsomes
in the presence of 1 mM NADP+ in 100 mM PBS with 1 mM MgCl2. Samples were collected at
0, 5, 10, 20, 30, and 60 min. The reaction was conducted at 37 ◦C before termination by addition of
ACN, and analysis was conducted by LC-MS/MS (similar to the method described above). Controls
with no drug and with no microsome regeneration system (buffer only) were included. All samples
were prepared in triplicate. The rate of degradation by metabolism was measured on the basis of
the difference of substrate concentration remaining at every time point. Metabolic half-lives were
calculated as mentioned above.
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4.5. Plasma Protein Binding
The in vitro plasma protein binding properties of B1 and D2 were investigated with the use of
Thermo Scientific™ rapid equilibrium dialysis polypropylene 96-well plates. Plate inserts comprised
two side-by-side chambers separated by a dialysis membrane (8K MWCO). The chambers contained
1100 µL plasma or 350 µL dialysis buffer (PBS buffer pH 7.4), respectively. Dogplasma lot was identical
to the one used in the plasma stability assay. Ten mM stock solutions of B1 and D2 were diluted
1:50 in water, and 200 µL of diluted B1, D2, and control compound (sarolaner, >99% protein bound)
were added to the wells containing plasma in an automated robot for liquid handling. Plates were
sealed and incubated at 37 ◦C for 4 h on a shaker. Each test was run in quadruplicate in dog plasma.
Upon completion of the assay, the plasma protein binding was determined by protein precipitation
with ACN of both plasma and PBS, and drug levels were quantified via LC-MS/MS as described above.
The percentage of bound compounds was determined from peak areas using Equations (3) and (4):
% free = (concentration buffer chamber/concentration plasma chamber) × 100% (3)
% bound = 100% − % free (4)
4.6. Formulation Preparation
An oil-in-water cream and an ointment were prepared as described by Danish Health and Medicines
Authority [64]. For the oil-in-water cream, ingredients of the oil phase (Table 3) were melted on a water
bath at 70 ◦C and mixed with the water phase, which was previously brought to boil and cooled down
to 65–70 ◦C. The mixture was stirred until cooled. The ointment formulation was prepared by mixing
melted Vaseline (80%) with paraffin oil (20%) on a water bath and allowed to cool under stirring. The cold
method was used for preparation of the 20% (w/w) poloxamer gel [65], where the poloxamer powder was
dissolved in purified water at 4 ◦C and subsequently left overnight at 2–8 ◦C to stabilize. All formulations
were stored at 4 ◦C for maximum seven days before use. Low doses of B1 or D2 were loaded into the
formulations just before initializing the release experiment by first dissolving an appropriate amount of
compound in 40 to 60 µL of water (or 96% ethanol in case of the ointment) and mixing this into 1 mL of
the formulation to obtain a final concentration of 600 µg/mL. For the hydrogel, the compounds dissolved
in water were mixed with the cold poloxamer solution before gelling at room temperature.
Table 3. Composition of the tested compounds.
Formulation Ingredients % (w/w)
Oil-in-water cream Oil Phase
Polysorbate 80 0.5
Cetostearyl alcohol 5
Paraffin oil 5
Glycerol monostearate 6
Water Phase
Methyl parahydroxy-benzoate 0.1
85% glycerol 4
Sorbitol 7
Purified water 72.4
Oinment
Paraffin oil 20
Vaselin 80
Hydrogel
Poloxamer 407 20
Purified water 80
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4.7. In Vitro Drug Release
The release of B1 and D2 from the formulations was determined by utilizing the Franz cell
apparatus. Approximately 200 µL of each formulation was filled into the donor chambers of the
Franz cells via a 1 mL syringe ensuring contact with the cellulose membrane separating the donor
compartment from the receptor compartment. The donor compartment was maintained at room
temperature (25± 1 ◦C) and the membrane diffusion area was 1.57 cm2. Activated cellulose membranes
(washed 3× with cold water and 3× with 100 ◦C warm water under stirring for 5 min) were used.
The receptor medium (3 mL PBS, pH 7.4) was stirred using magnetic stirring and thermo-regulated to
36 ◦C by a water jacket. Samples (200 µL) were collected from the receptor compartment through the
sampling port over 8 h, and the withdrawn volume was replaced with an equal volume of buffer at
every time point. The samples were analyzed by a Waters 600E RP-HPLC equipped with Empower 3
software (Waters Corporation, Milford, MA, USA): 30 min run time with 20 min linear gradient from
0.1% (v/v) TFA in water to 30% (v/v) ACN:H2O with 0.1% (v/v) TFA (90:10). The amounts of B1 and
D2 released and diffused through the cellulose membrane were determined using the calibration curve
as previously described. Experiments were performed in duplicate.
4.8. Skin Permeation
The amount of B1 and D2 that permeated excised dog skin using three different vehicles was
determined ex vivo on an automated Franz cell apparatus. B1 and D2 were dissolved (10 mg/mL) in
20 mM sodium acetate buffer pH 5, in 50% (v/v) ethanol and in 50% (v/v) diethylene glycol monoethyl
ether (Transcutol®) in sodium acetate buffer. Skin obtained from the dorsal side of Beagle dogs was
pre-treated and stored at −20 ◦C until use. Pre-treated skin was partially shaved and consisted of
stratum corneum (SC) and epidermis. On the day of the experiment, the skin was thawed at room
temperature (RT) for one hour, cut in circles (diameter ≈ 2 cm), and stored at RT for 1 h prior to
experiments. A circulating water bath was used to keep the cells at a temperature of 37 ◦C. Polysorbate
80 was used in the receptor chambers (containing 10 mL) to avoid non-specific binding of B1 and D2
to the glass. Prior to the experiment, the receptor chamber solution was degassed for 30 min at RT.
Cells were primed and rinsed three times with 10 mL water and three times with 10 mL polysorbate
80 solution. The skin was then mounted on the diffusion cells with the SC facing upwards towards
the donor compartment. Transepidermal water loss (TEWL) was measured for each piece of skin
independently at the start of the experiment by utilizing Delfin VapoMeter in contact for 10 s with
the skin mounted on the chamber. The receptor chambers were subsequently filled with further
10 mL polysorbate 80 solution and left to equilibrate for 150 min. Donor chambers contained 100 µL
of formulation added in two steps (2 × 50 µL). Permeation experiments were conducted for 48 h,
and donor chambers containing Transcutol® were covered with tin foil to avoid any light exposure.
At predetermined time points (2, 6, 12, 24, and 48 h), 1 mL of the receptor phase was withdrawn and
replaced with the same amount of receptor medium. The amount of B1 and D2 in the withdrawn
samples was determined by UPLC analysis. The experiment was conducted in duplicate.
5. Conclusions
In conclusion, the novel antimicrobial peptide-peptoid hybrid B1 and peptoid D2 displayed
properties suitable for the topical treatment of S. pseudintermedius infections in, e.g., an oil-in-water
cream and metabolic stability. The positively-charged peptoid-based molecules were found to not
penetrate skin, thus, rendering them suitable for topical application when no systemic absorption is
desired (e.g., to treat superficial pyoderma). Although in vitro results need to be confirmed by in vivo
data, our results show how the presence of peptoid residues correlates with increased stability at
conditions resembling in vivo metabolism and possibly with a decreased degree of hemolysis. To the
authors’ knowledge, this study represents the first characterization of in vitro early ADME properties
of peptoid-based antimicrobials.
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Supplementary Materials: Supplementary materials are available on line. Table S1: Gradient elution used for
purification of compounds on preparative RP-HPLC. Table S2: Gradient elution used for analytical RP-HPLC ,
Table S3: Retention times, peak areas and relative peak areas of D2 as detected by RP-HPLC., Table S4: Final gradient
elution UV-UPLC method used for the LC-MS/MS experiments., Table S5: Half-lives of peptide-peptoid hybrid
B1 and peptoid D2 measured after 60 minutes of incubation at 37◦C with dog plasma; Figure S1: Analytical
HPLC chromatogram of compound B1, Figure S2: MALDI-TOF MS spectrum of B1, Figure S3: Analytical HPLC
chromatogram of compound D2, Figure S4: MALDI-TOF MS spectrum of D2, Figure S5: Stability of D2 to pronase E,
Figure S6: B1 in 50% Transcutol in acetate buffer pH 5 detected via UV-UPLC (day 0), Figure S7: B1 in 50% Transcutol
in acetate buffer pH 5 detected via UV-UPLC (Day 1), Figure S8: Concentration-time profile in plasma of the
compounds B1 and D2.
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